Invitation to presentation of Cantargia’s report for the third quarter of 2021 on November 11 at 3.00 p.m. CET
Cantargia AB will publish the company’s report for the period July – September 2021 on Thursday, November 11, 2021, at 08.30 a.m. CET.
In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on November 11, at 3:00 p.m. CET, where Göran Forsberg, CEO, and Bengt Jöndell, CFO, will present Cantargia and comment on the quarterly report for the period July – September 2021, followed by a Q&A-session.
The conference call can be followed at: https://tv.streamfabriken.com/cantargia-q3-2021
To attend through telephone, please dial-in at one of the numbers below:
SE: +46 8 50558368
UK: +44 3333009267
The webcast will also be available on demand on Cantargia’s corporate website: www.cantargia.com
For further information, please contact:
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
This information was submitted for publication, at 13:00 CET on 8 November 2021.
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. The main project, the antibody nadunolimab (CAN04), is being studied clinically in combination with chemotherapy or immune therapy with a primary focus on non-small cell lung cancer and pancreatic cancer. Positive interim data from the combination with chemotherapy indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia’s second project, the antibody CAN10, addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.